Remove 2026 Remove Pharma Remove Physicians
article thumbnail

Health consumers: A long way off

World of DTC Marketing

Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. By 2026, national health expenditures will reach $5.7 It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism. It’s a good read but ignores a simple fact.

article thumbnail

A Look Into Telehealth in 2021 and Beyond

Pharma Marketing Network

Billion by 2026 with a CAGR of 37.2% Physicians and patients raise legitimate questions and concerns about the safety, effectiveness, and accessibility of telehealth. Wearable technology allows physicians to check in on the health of their patients in between physical office visits. Billion in 2019 and Expected to Reach USD 171.81

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. VillageMD’s rollup continued with a March 3 announcement that it was acquiring Starling Physicians, a Connecticut-based physician group, expanding its footprint to 680 practice locations in 26 markets.

article thumbnail

Making Sense of the Latest Changes to the Market Access Landscape

PM360

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

Dan Renick The IRA presents market access teams with a unique opportunity to make recommendations to CMS regarding the evidence and methodology that will be applied in evaluating drugs for upcoming Medicare negotiations that will lead to price adjustments in 2026. Quality and value measurements commonly used outside of the U.S.

article thumbnail

Specialty Treatments Require a New Approach to Affordability

PM360

GoodRx is the leading platform 2 with the highest unaided awareness and trust across patients, physicians, and pharmacists 3 that Americans—regardless of insurance status—use across many phases of their healthcare journey. United States Specialty Pharmaceuticals Market & Forecast 2020-2026,” BusinessWire, December 8, 2020.